Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients by Daniel C. Malone, Rebecca Dean, Ramesh Arjunji, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru, Douglas M. Sproule, Douglas E. Feltner, Omar Dabbous

Get full text

An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and... by Rebecca Dean, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru, Douglas M. Sproule, Douglas E. Feltner, Thomas Wiesner, Daniel C. Malone, Matthias Bischof, Walter Toro, Omar Dabbous

Get full text

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors by Douglas E Feltner, Adil Daud, Brent A Hanks, Shailender Bhatia, Michael K Wong, Sunandana Chandra, Trisha M Wise-Draper, Philip A Friedlander, Melissa A Burgess, Glenn J Hanna, C Lance Cowey, George Ansstas, Ciara M Kelly, Mohammed M Milhem, Cesar A Perez, Ryan M Weight, Alice S Bexon, Douglas E Laux, Theresa M Medina, Steven J O’Day, Timothy S Kristedja, Weston L Daniel, Scott Mix, Laurel Sindelar, Martin F Bexon, Robert E Michel

Get full text